Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HCID 516951생성일: 2026년 10월 27일
칼륨 인산염
칼륨인산염 · 칼륨인산염(POTASSIUMPHOSPHATE) · phosphoric acid, potassium salt · phosphoric acid potassium salt,>97% · Phosphoric acid, potassium salt (1:)
https://huagongshe.com/ko/chemical/516951
식별자 및 물리적 특성
| CAS No. | 16068-46-5 |
|---|
| 분자식 | KH2PO4 |
|---|
| 평균 분자량 | 136.086 g/mol |
|---|
| 단동위원소 질량 | 135.93277685 g/mol |
|---|
| SMILES | O=P([O-])(O)O.[K+] |
|---|
| InChIKey | GNSKLFRGEWLPPA-UHFFFAOYSA-M |
|---|
| PubChem CID | 516951 |
|---|
| ChEMBL | CHEMBL1200925 |
|---|
| ChEBI | CHEBI:63036 |
|---|
| EC No. | 231-913-4 |
|---|
| DTXSID | DTXSID0035667 |
|---|
| 현지명 | 칼륨 인산염 |
|---|
화학 및 물리적 성질
| 극성 표면적 | 80.6 |
|---|
| 수소 결합 공여자 수 | 2 |
|---|
| 수소 결합 수용자 수 | 4 |
|---|
| 회전 가능 결합 수 | 0 |
|---|
| 무거운 원자 수 | 6 |
|---|
| 형식 전하 | 0 |
|---|
| 복잡도 | 61.9 |
|---|
| 물질 분류 | Metals -> Phosphates, Metallic Salts |
|---|
| 화장품 | Cosmetic ingredients (Potassium Phosphate) -> CIR (Cosmetic Ingredient Review)Buffering |
|---|
| pH | Between 4,2 and 4,8 (1 % solution)pH = 4.4 to 4.7 |
|---|
| SpringerMaterials Properties | thermal expansion coefficient |
|---|
| 냄새 | Odorless |
|---|
| 식품 첨가물 | MALTING OR FERMENTING AID, NUTRIENT SUPPLEMENT, PH CONTROL AGENT, STABILIZER OR THICKENER -> FDA Substance added to food |
|---|
| 밀도 | 2.34 g/cu cm2.34 g/cm³ |
|---|
| Color/Form | Colorless crystals or white granular powderWhite tetragonal crystals |
|---|
| 용해도 | Freely soluble in water. Insoluble in ethanolSolubility: 18 g/100g water /Monopotassium phosphate anhydrous/Soluble in about 4.5 parts waterinsoluble in alcoholSolubility: 25 g/100 cc water at 25 °C. Slightly soluble in ethanolSolubility in water, g/100ml: 22 |
|---|
| Human Drugs | FDA approved drugs -> Active ingredient |
|---|
| Animal Drugs | Active Ingredients (Potassium Phosphate) -> FDA Greenbook |
|---|
| 녹는점 | 253 °C |
|---|
| 화장품 원료 기능 | 버퍼링 |
|---|
| EPA | Phosphoric acid, potassium salt (16068-46-5) |
|---|
안전 및 규제
| GHS 분류 | This chemical does not meet GHS hazard criteria for 90.7% (794 of 875) of all reports.Not ClassifiedAggregated GHS information provided per 875 reports by companies from 16 notifications to the ECHA C&L Inventory. |
|---|
| 규제 정보 | Chemical: Phosphoric acid, monopotassium saltPhosphoric acid, potassium salt (1:1) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Phosphoric acid, potassium salt (1:1) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)Phosphoric acid, potassium salt (1:?) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Phosphoric acid, potassium salt (1:?) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)Status: Active Update: 11-04-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/15471Potassium phosphate, monobasic: Does not have an individual approval but may be used under an appropriate group standard |
|---|
| 기타 안전 정보 | IMAP assessments - Phosphoric acid, monopotassium salt: Environment tier I assessment |
|---|
| 화재 위험 | Not combustible. Gives off irritating or toxic fumes (or gases) in a fire. |
|---|
| 유해성 요약 | A skin, eye, and respiratory tract irritant[ICSC] Emergency treatment: Inorganic phosphatesInorganic phosphates can cause diarrhea, hyperphosphatemia, and hypocalcemia after ingestionAn adult died after receiving four sodium phosphate enemas within 24 hourshe had electrolyte abnormalities and died from cardiac arrest[HSDB] |
|---|
| FDA 요건 | The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl potassium phosphate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.Potassium phosphates (mono, di, and tribasic) are indirect food additives for use only as components of adhesives. |
|---|
| Special Reports | WHO |
|---|